

Contents

SECTION 1 Basic Science, Clinical and Ethics

1. **Macrophage, the Guardian of the Heart Beat**3
Partha Sarkar, Sujoy Sarkar
2. **Hypertension: Sodium Intake and Myocardial Function**7
Harsh Wardhan, Umesh Kumar Pandey
3. **Searching for a Link between Metabolic and Cardiovascular Diseases: Diet and Inflammation** 13
Kuntal Bhattacharyya, Snehil Goswami, Koushik Dasgupta
4. **How Far Ancestry versus Traditional Risk Factors Predict the Risk of Future CV Events?** 18
Arup Dasbiswas, Swati Lad, Ashwini Patil
5. **Cardiac Cell Therapy using Tissue Engineering**..... 25
Saubhik Kanjilal
6. **Air Pollution and Cardiovascular Diseases**..... 32
Dibyajyoti Dutta, T Karthikeyan
7. **Epicardial Obesity Significant Predictor of Multifocal Atherosclerosis**..... 36
Asha Moorthy, Jain T Kallarakkal
8. **Role of Glycated Proteins in Atherogenesis**..... 39
A Muruganathan, M Gowri Sankar
9. **Is the Funeral of Clinical Examination Declared?**..... 45
Dibbendhu Khanra, Ashwin Kodliwadmath
10. **Ethical Considerations in Cardiology Practice: Is the Curriculum Enough? Or is it Time to Change?** 61
Vitull K Gupta, Meghna Gupta, Varun Gupta

SECTION 2 General Cardiology

11. **Cardiovascular Disease Prevention: What the Guidelines Have to Offer** 69
Shishu Shankar Mishra, Biswaranjan Mishra, Satyanarayan Routray
12. **Sex after Major Cardiovascular Illness** 77
Deepak K Juman
13. **Acute Coronary Syndromes: Physiologic Predictors for Optimal Therapy** 83
Anil Kumar, Vikrant V Deshmukh, Aditya Gupta

14. **Recent Trials in Cardiology**..... 89
Dinkar Bhasin, VK Bahl
15. **Sleep Disorder: Is it the Holy Grail of Cardiometabolic Syndrome?**..... 97
S Ramnathan Iyer, Revati R Iyer

SECTION 3 Epidemiology and Bio-Statistics

16. **Evolution of Cardiovascular Trials vis-a-vis Indian Scenario Going GLOCAL - from GLObal Cardiovascular trial evidence to improving Local outcomes**..... 109
Deepak Kamath, Dhiraj RS, Denis Xavier
17. **Integrating Data Collection Initiatives to National Non-communicable Disease Program: Ensuring Non-duplication of Valuable Efforts**..... 118
Chayan Vermani, Faraz Ahmed Farooqui, Sivasubramanian Ramakrishnan
18. **Challenges in Epidemiological or Hospital-Based Data Collection in India** 123
K Venugopal

SECTION 4 Preventive Cardiology

19. **Yoga, An Adjunctive Therapy in Cardiovascular Disease Management**..... 129
RK Kotokey
20. **Yoga: Is it Medicine for Cardiovascular Disease?** 133
SC Manchanda, Kushal Madan

SECTION 5 Womens' Heart

21. **Cardiovascular Disease in Women: A Clinical Over** 141
T Indrani, Sudhir R Naik, C Venkata S Ram
22. **Chest Pain in Women: Evaluation and Management**..... 153
IB Vijayalakshmi
23. **Risk Factors for Coronary Heart Disease and Heart Failure Specific to Women** 167
M Jyotsna, V Satish Kumar Rao
24. **Pregnancy with Congenital Heart Disease** 178
Anita Saxena
25. **Pregnancy-induced Hypertension: Latest Views** 186
Harendra Kumar

26. How to Wage Red War in India against the Menace of Cardiovascular Disease in Indian Women 190
Lipika Adhikari

SECTION 6 Hypertension

27. Diurnal Changes, BP Variability, and Risk of Cardiovascular Events 199
Sumanta Chatterjee
28. Ambulatory Blood Pressure Monitoring: Is the Ultimate for Hypertension Diagnosis, Risk Assessment and Therapeutic Evaluation 203
Gaurav Singhal, Deepesh Agrawal
29. Challenges Posed by Increasing Prevalence of Pre-Hypertension and Undetected Hypertension in India 209
Raashi Raj, Manu Raj Mathur, D Prabhakaran
30. Combination Therapy, Not Monotherapy is the Solution for Blood Pressure Control: A Guideline-based Approach 217
Mohsin Wali, C Venkata S Ram
31. Resistant Hypertension or Physician Inertia-mediated Hypertension? 228
Anjan Lal Dutta, Soumik Chaudhuri
32. Decreasing BP Targets: Our Perspective in Indian Guidelines for Hypertension 238
Suraj Kumar, Abhishek Goyal, Gurpreet S Wander

SECTION 7 Rheumatic Heart Disease and Infective Endocarditis

33. What is New in Rheumatic Fever and Rheumatic Heart Disease? 245
Debasish Banerjee, Subhayan Bhattacharya
34. Options in Prevention of Rheumatic Heart Disease with Non-availability of Penicillin 252
Partha Sarathi Karmakar
35. Contemporary Issues in Rheumatic Fever and Chronic Rheumatic Heart Disease 256
Bhuban Majhi, Nandita Pal
36. Long-term Oral Antibiotic Therapy in Infective Endocarditis: Is It Real? 262
Arnab Datta
37. Dental and Cardiovascular Health: Invasive Dental Management versus Infective Endocarditis 269
Swapn De, Trilochan Agarwal

SECTION 8 Dyslipidemia

38. **Dyslipidemia in Indians and Caucasians: How Do They Vary? How to Tackle?** 275
Ranjit Nath, Neil Bardoloi
39. **Epidemiology of Dyslipidemias in India, Emigrant Indians and Global Comparisons: More Similar than Different** 281
Rajeev Gupta, Sonali Sharma
40. **Does Hypertriglyceridemia in Indians Require Treatment? What are the Evidences?** 293
Udas Chandra Ghosh, Md Hamid Ali
41. **LDL in Fasting versus Nonfasting Stage: Does it Matter in Management?** 302
Geetha Subramaniam, J Cecily Mary Mjella, Mohammad Kaleem, Abhishek Kaushley
42. **High-density Lipoprotein Cholesterol Paradox: Is there Any Solution?** 309
Devanu Ghosh Roy
43. **Prediction of Imminent Pulmonary Edema in Acute Heart Failure is Feasible: Role of Intrapulmonary Devices and Lung Ultrasound** 313
Ashish Jai Kishan, Atul Mathur
44. **New Insights on High Density Lipoprotein** 322
Mriganka S Chaliha
45. **Lipoprotein(a): Should It Be Belittled?** 333
SS Iyengar, KS Roplekar
46. **Familial Hypercholesterolemia: An Orphan Field—Underdiagnosed and Undertreated** 341
JPS Sawhney, Kushal Madan, Nitika Setia
47. **Y-Y Paradox: Why Is It Important?** 347
Manish Kapoor, Ashish Hota
48. **Adverse Effects of Statins: Real or Myth? Message to Statin Sceptics** 355
Saumitra Ray
49. **Should We Stop Statins after Statin-induced Myopathy Disorder in All? What Are the Pitfalls?** 361
Kashinath Ghosh Hazra, Purushottam Kumar

SECTION 9 Ischemic Heart Disease

50. **Are the New Risk Factors for Coronary Artery Disease Relevant?** 369
Spandan Bhadury
51. **Spontaneous Coronary Artery Dissection and Management Strategies** 376
Pawan K Sharma, HK Chopra

52. **SCAD or ACS: Does the Combination of DAPT After Stenting Matter?** 383
Narender Omprakash Bansal, Gurkirat Singh
53. **How to Manage Coronary Artery Disease in Chronic Kidney Disease Stage 4 or 5 during Coronary Interventions?** 390
Dibya Kumar Baruah, Srikanth Bodepudi

SECTION 10 STEMI

54. **Prevalence and Management of Myocardial Infarction with Non-obstructive Coronary Arteries** 399
Alok Mazumdar
55. **Biomarkers in Acute Myocardial Infarction** 405
TK Mishra
56. **Which Thrombolytic to Choose for STEMI in India?** 412
Jayanta Saha, Basabendra Choudhury, Shravan Kr, Anjan Hembram
57. **Adjunctive Pharmacotherapy in STEMI** 425
Kewal C Goswami, Siddharthan Deepti
58. **Coronary Stenting is the First Option in ST-elevation Myocardial Infarction Presenting in the First Hour** 441
Suman Bhandari, Anunay Gupta, Rajat Jain
59. **What are the Specific Substrates of STEMI for Thrombectomy?** 447
Jabir Abdullakutty, Musna PJ, Jimmy George
60. **Management of Patients Presenting Late after STEMI** 453
Pravesh Vishwakarma, Johann Christopher, Akshyaya Pradhan, Rishi Sethi
61. **Has the Clock Reversed for the Management of STEMI in India?** 464
Sandeep Bansal, Anunay Gupta, Gunjan Garg
62. **How Better is the Deferred Stenting for STEMI with Thrombus?** 469
TR Raghu, Sathwik Raj VA, Jayashree Kharge

SECTION 11 Anti Platelet and Anti-Coagulants

63. **Are the Days of Aspirin Numbered?** 475
Dilip Kumar, Rana Rathor Roy, Rabin Chakraborty
64. **How to De-Escalate P2Y₁₂ Receptor Inhibitor after Percutaneous Coronary Intervention?** 481
Kanak Kumar Mitra, Uday Sankar Das, Ajinkya Vijay Mahorkar

65. Long-term Prevention of Atherothrombosis after ACS: How to Ensure.....	487
Satyendra Tewari, Paritosh Kumar Rajput	
66. Dual Anti-Platelet Therapy After Percutaneous Coronary Interventions: Ischaemic Vs Bleeding Risks.....	494
Satyavir Yadav, Saurabh Mehrotra, Sundeep Mishra	
67. Expanding Use of NOACs	506
Raja Ray	
68. Which is the Best Parenteral Anticoagulant? Why and What are the Indications?	513
Dharmendra Jain, Mohammad Kaleem, Abhishek Kaushley	
69. Managing Anticoagulation in Liver Diseases	521
AK Pancholia	

SECTION 12 Atrial Fibrillation

70. Atrial Fibrillation: Modifiable Risk Factors	531
Raghav Bansal, Yash Lokhandwala	
71. Is Atrial Fibrillation a Preventable Disease?	538
Biswajit Majumder, Sandip Ghosh	
72. Detection of Atrial Fibrillation: How can the Technology Help?	546
Chandra Bhan Meena, Shekhar Kunal	
73. Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention "One Size Cannot Fit All"	556
Pankaj Manoria, PC Manoria, Pooja Singh	
74. Demonic Trio of CAD, HF, and AF: Are We Clear Conceptually? How to Manage Medically?	561
PB Jayagopal, SKM Sarjun Basha	
75. Issues and Challenges in Stroke for Cardiologists.....	568
Santanu Guha, Siddhartha Mani	
76. Does Cryptogenic Stroke Warrant Interventional Therapy?	574
Sukumar Ghosh, Mukesh Palsania	
77. Ablation of Atrial Fibrillation: How Far Have We Achieved?	578
Aftab Khan, Asit Das	
78. Oral Anticoagulation in Heart Failure	587
Sharad Agrawal	
79. Nonvitamin K Antagonists "Will They Alone Command Management of Heart Failure"	593
Ajay Kumar Sinha, Vikas Singh, Nishant Tripathy	

SECTION 13 Heart Failure

80. Heart Failure with Preserved Ejection Fraction..... 599
Anil Dhall
81. Approach to Heart Failure with Midrange Ejection Fraction:
Is it Improvement from HFrEF or Deterioration of HFpEF? 618
Shaheer Ahmed, Ambuj Roy
82. Biomarkers for Heart Failure: How Do They Influence Treatment and Management? 623
Sankar Chandra Mandal, Soumya Kanti Dutta, Avinav Anand
83. Beta-blockers in Heart Failure: From Controversy to Consensus 627
AK Pancholia, HK Chopra
84. Novel Considerations in Optimizing Care of Heart Failure Patients 634
Soumitra Kumar, Koushik Das Gupta
85. Diagnostic and Therapeutic Algorithms for Treatment of Heart Failure in India 646
Harikrishna D
86. Angiotensin Receptor Neprilysin Inhibitor for All with
Heart Failure with Reduced Ejection Fraction 650
Surender Deora, Kewal C Goswami
87. Between Devil and Deep Blue Sea Heart Failure
Therapy vis-a-vis Worsening Renal Function..... 658
PS Banerjee, Samir Prajapati
88. Between Scylla and Charybdis: How to Balance Hypotension and
Pulmonary Edema in Patient Admitted with Acute Decompensated HF? 665
Kajal Ganguly, Anindiya Mukherjee, Debajyoti Dutta
89. Challenges in Heart Failure Management: Any Role of Ambulatory Inotropes Infusion..... 673
VK Katyal, Sandeep Goel, Sanjay Fotedar
90. Inotropes or Inodilators in Heart Failure with Reduced
Ejection Fraction: What to Use, On Whom, When and How? 677
Kewal C Goswami, Surender Deora

SECTION 14 Cardiomyopathy

91. Takotsubo Syndrome: How to Manage?..... 689
Dipankar Ghosh Dastidar
92. Premature Ventricular Complex-mediated Cardiomyopathy: How to Manage? 706
Nirmal Ghati, Siddharthan Deepti, Nitish Naik

93. **Hypertrophic Cardiomyopathy: How the Septal Ablation Therapy Fares as Compared to Myectomy?** 716
Dipankar Mukhopadhyay, Palden Wangchuk Bhutia, Subir Sen
94. **Has the Therapeutic Journey for Hypertrophic Cardiomyopathy Borne Full Cycle** 721
Harinder K Bali, Amreen Dhindsa
95. **Endomyocardial Biopsy: Has Cardiac MRI Reduced its Relevance?** 732
KK Talwar, Sudheer Arava

SECTION 15 Congenital Heart Diseases and Pulmonary Hypertension

96. **What is New in the Management of Pulmonary Hypertension?** 743
Ananda Bagchi, Aradhya Sekhar Bagchi
97. **Physiology of Fontan Operation: Complications and Management** 753
Kothandam Sivakumar

SECTION 16 Structural Heart Disease

98. **Concepts of Heart Failure** 767
Sankar Paul Chowdhury, Manish Saha, Satish Ramteke
99. **Why Can't We Extrapolate Degenerative Valve Disease to Rheumatic Valve Disease during Percutaneous Interventions?** 776
Vijay H Bang, Charan Reddy KV
100. **Challenges, Controversies, and Future of Interventional Therapy for Mitral Valve Regurgitation** 785
Anoop Titus, Ramesh Daggubati
101. **Overview of Transcatheter Aortic Valve Replacement: How to Evaluate for Safe and Successful Outcome** 797
Edgar Tay
102. **Right Ventricular Outflow Tract Stenting in Severe Tetralogy of Fallot** 799
Amitabha Chattopadhyay, Aritra Mukherji, Sanjiban Ghosh

SECTION 17 Percutaneous Coronary Intervention

103. **Vulnerable Plaque versus Vulnerable Patients: How to Define?** 807
Parayoru Kottayil Asokan, Kailash Kumar Goyal
104. **Invasive Hemodynamic Assessment of Coronary Stenosis: Utility and Pitfalls** 812
Sreenivas Kumar Arramraju, Ramakrishna Janapati

105. **Radial Access is the Route of Choice for Percutaneous Coronary Intervention: Good, Bad, and Ugly** 820
Sanjay Kumar Chugh
106. **Management of Unstable Angina beyond Optimal Medical Therapy, Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery** 826
Neelkanth G Karandikar, Hiren Prajapati
107. **Are There Drugs to Take Care of Coronary Restenosis?** 834
CG Bahuleyan, Viswanatha Kartik S
108. **Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction with Late Presentation: Is it Justified?** 842
Ashesh Halder, DP Sinha
109. **Culprit Vessel or Multivessel Percutaneous Coronary Intervention during Primary Angioplasty in Myocardial Infarction: Which One to Adopt?** 851
Dev B Pahlajani
110. **B-type Natriuretic Peptide: Mortality Risk Assessor and Clinically Actionable Information Marker for Obstructive Left Main Disease** 857
B Kesavamoorthy, C Sunder, Niranjana Kesavamoorthy
111. **Enigma of Bifurcation Lesions: Have We Seen the Light at the End of Tunnel?** 860
Shuvanan Ray, Sabyasachi Mitra
112. **Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock** 864
Varsha Koul, Upendra Kaul
113. **Future of Stent Therapy in India: An Interventionalist's View** 870
Lekha Adik Pathak, Ronak V Ruparelia
114. **What is the Future of Stent Therapy in India? The Clinician's View** 875
Justin Paul G, Deepak Shejol, Elavarasi Manimegalai
115. **Polymer-free Drug-eluting Stents: A New Paradigm for Treating High Bleeding Risk Patients** 880
Vikas Singh, Ajay Kumar Sinha
116. **Multivessel CAD: PCI? CABG? Standalone Medical Therapy?** 886
Saujatya Chakraborty, Sunip Banerjee
117. **New Era Drugs for Unstable Angina** 891
Dibbendhu Khanra, Shishir Soni
118. **What is New in Intravascular Ultrasound? Proposal for a Predictive Model That Can Change Outcomes in Distal Left Main Percutaneous Coronary Intervention** 903
Debdatta Bhattacharyya, Ayan Kar, Pushpita Bhattacharyya

119. **Optical Coherence Tomography in Percutaneous Coronary Intervention:
How it has Made the Lives of the Patient and Operator Easy.....** 907
G Sengottuvelu, P Vinodh Kumar
120. **Optical Coherence Tomography is the Future in Coronary Intervention.....** 915
Balbir Singh, Prateek Chaudhary

SECTION 18 Chronic Total Occlusion

121. **Chronic Total Occlusion: The Final Frontier of Percutaneous Intervention** 923
Ashwin B Mehta, Nimesh Jain
122. **Is It Worth Spending on Chronic Total Occlusion Management:
Algorithm for the Value for Money.....** 933
Prathap Kumar N, Manu Rajendran, Stalin Roy J

SECTION 19 Peripheral Vascular Disease

123. **Diagnosis, Medical and Interventional Management
of Aortoarteritis (Takayasu Arteritis)** 943
Monotosh Panja, Madhumanti Panja
124. **Abdominal Aortic Aneurysm: Dangers and Mitigation by Intervention.....** 955
Suparna Rao, NN Khanna

SECTION 20 Device Therapy for Heart Failure

125. **Implantable Cardioverter Defibrillators in Patients with
Nonischemic Dilated Cardiomyopathy.....** 969
Raja J Selvaraj, Balachander Jayaraman

SECTION 21 Echocardiographic

126. **Challenges in Evaluation of Athletes' Heart** 975
Shantanu P Sengupta, Manas Bindra
127. **Evaluation of Diastolic Dysfunction by Echocardiography:
Have We Reached the End of the Road?** 982
Sunil Lhila, Sougata Sanyal, Sunandan Sikdar

- 128. How has Transesophageal Echocardiography Changed the Practice of Cath Lab Interventions? 988**
Manish Bansal
- 129. Strain Imaging in Asymptomatic Aortic and Mitral Valve Regurgitation: Predicting Optimal Timing for Intervention 1002**
Jagdish C Mohan, Madhu Shukla, Vishwas Mohan
- 130. Echocardiographic Imaging for Sub-Clinical Myocardial Impairment 1013**
Aniruddha De
- 131. 3D Echocardiography: Making the Most of It..... 1023**
V Amuthan, RVA Ananth
- 132. Usefulness of Three/Four Dimensional Echocardiography in Clinical Practice 1041**
Ahmed S Aboeata, Aiman M Smer, Navin C Nanda

SECTION 22 Imaging

- 133. New Onset Heart Failure: Role of Cardiac MRI in Assessment, Risk Prediction and Follow-up..... 1055**
Mona Bhatia, Parveen Kumar, Shashank Jain, Amit Garg
- 134. Multimodality Imaging in Ischemic Cardiomyopathy 1069**
Johann Christopher, Mohd Mansoor Mohiuddin
- 135. How Advance Imaging Can Differentiate between Chronic Pericarditis and Restrictive Cardiomyopathy 1084**
ST Yavagal
- 136. Role of Nuclear Cardiology in Diagnosis, Prognosis and Risk Stratification of Patients with Coronary Artery Disease in 2019 1092**
GN Mahapatra

SECTION 23 Cutting Edge Technology in CVD

- 137. Emerging Role of Impedance Cardiography: A New Tool 1111**
Bhabani Prasad Chattopadhyay, Sudipta Ghosh, Rammohan Roy, Nasim Mandal, Kalyan Saha
- 138. Artificial Intelligence and Cardiology 1115**
Abhishek Roy, Debabrata Roy
- 139. Machine Learning and its Application in Echocardiography 1129**
Mansi Kaushik, Ravi R Kasliwal, Manish Bansal
- 140. 5G and Cardiovascular Health..... 1137**
Sar bani Barari, Mrinal Kanti Das

SECTION 24 Miscellaneous

141. ECG Changes in Athletes: How to Prognosticate?	1147
Gopal Chandra Ghosh, Suvro Banerjee	
142. Syncope of Unknown Origin: What are the Challenges in Evaluation and Management?	1152
Pranab Jyoti Bhattacharyya	
143. Success and Failure Story of In-Hospital Cardiac Arrest.....	1158
Amal Kumar Khan, Subhasis Roy Chowdhury, Amartya Khan	
144. DM-CVD in Types 1 & 2 DM	1162
Anurag Arora, Dhrub Kumar	
145. SGLT2 Inhibitor: Is it the Panacea for Diabetes Mellitus with Heart Failure?.....	1172
BP Singh, Ravi Vishnu Prasad, Nirav Kumar, Gautam Kumar	
Index.....	1181